We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

96 hedge funds and large institutions have $586M invested in Aclaris Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more call options, than puts

Call options by funds: $1.46M | Put options by funds: $675K

38% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 29

9% more capital invested

Capital invested by funds: $536M → $586M (+$50.4M)

1.35% more ownership

Funds ownership: 98.94% → 100.29% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 100 → 96 (-4)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

Holders
96
Holders Change
-4
Holders Change %
-4%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
40
Reduced
29
Closed
15
Calls
$1.46M
Puts
$675K
Net Calls
+$782K
Net Calls Change
+$1.04M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.7M
2
Franklin Resources
Franklin Resources
California
+$7.3M
3
RSCM
Rock Springs Capital Management
Maryland
+$6.02M
4
BlackRock
BlackRock
New York
+$3.77M
5
RHJA
Rice Hall James & Associates
California
+$3.47M

Top Sellers

1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$9.24M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.51M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.28M
4
HCM
Highbridge Capital Management
New York
-$5.26M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$67M +$14.7M +796,805 +31%
Franklin Resources
2
Franklin Resources
California
$59.3M +$7.3M +395,074 +15%
DM
3
Deerfield Management
New York
$54.8M – – –
BlackRock
4
BlackRock
New York
$46.2M +$3.77M +204,215 +10%
VC
5
Vivo Capital
California
$32.9M – – –
SI
6
Sofinnova Investments
California
$30.7M – – –
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$25.3M +$566K +30,629 +2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$23.9M +$543K +29,414 +3%
Citadel Advisors
9
Citadel Advisors
Florida
$17.3M -$529K -28,607 -3%
RSCM
10
Rock Springs Capital Management
Maryland
$17.1M +$6.02M +326,000 +62%
Westfield Capital Management
11
Westfield Capital Management
Massachusetts
$15M +$743K +40,235 +6%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$14M -$5.28M -285,865 -29%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$12.3M -$4.4M -238,139 -28%
DCM
14
Driehaus Capital Management
Illinois
$11.7M -$110K -5,968 -1%
Invesco
15
Invesco
Georgia
$11.5M +$203 +11 +0%
State Street
16
State Street
Massachusetts
$11.1M -$120K -6,517 -1%
MWNA
17
Marshall Wace North America
New York
$10.6M -$2.87M -155,381 -23%
FCMI
18
Foresite Capital Management IV
California
$10.6M +$1.85M +100,000 +23%
CAM
19
Cormorant Asset Management
Massachusetts
$10.5M – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
$8.45M +$579K +31,339 +8%
RHJA
21
Rice Hall James & Associates
California
$7.97M +$3.47M +187,545 +89%
Axa
22
Axa
France
$7.63M +$1.61M +87,250 +30%
FCMI
23
Foresite Capital Management III
California
$6.24M – – –
Northern Trust
24
Northern Trust
Illinois
$5.89M -$9.94K -538 -0.2%
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$5.39M -$8.51M -460,452 -63%
1
2 3 4 5

ACRS Hedge Fund Activity: Q2 2018 in Review

96 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2018, worth a combined $586M — up 9.4% from $536M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ACRS and 12 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 40 added.

The largest buyer was Fidelity Investments, adding an estimated $14.7M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $9.24M sold.

  • 96 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2018, down from 100 in Q1 2018.
  • Funds reported $586M of Aclaris Therapeutics stock for Q2 2018, up 9.4% quarter-over-quarter.
  • 12 funds opened new Aclaris Therapeutics positions in Q2 2018 and 15 closed out, a net change of -3 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2018 was Fidelity Investments, an estimated $14.7M added.
  • The largest Aclaris Therapeutics seller in Q2 2018 was Loomis, Sayles & Company, an estimated $9.24M sold.

Based on aggregated 13F filings for Q2 2018.